BOSTON KPro news Antimicrobial prophylaxis for life: FALL 2011 | NUMBER 8 as important as ever

However, it has become increasingly clear that very small amounts of antibiotics applied topically every day to the operated eye can be very effective in preventing bacterial infections. While this seems counterintuitive, our experience gained from thousands of KPro cases indicates that daily application of a light prophylaxis can be effective for many years without complications; it is also clear that, without any prophylactic antibiotics, the risk of infection is still very high. On the other hand, an excess of antibiotics can make the eye susceptible to fungal infections. Therefore, choosing the right antibiotic in the right concentration is very important for the long-term success of keratoprostheses. While many surgeons recommend ata drawn from thousands the most common culprit. Infections different regimens, the procedures of keratoprosthesis cases is rarely occur during the first few months we follow in Boston have been very showing that the judicious use postoperatively, but may surface D effective and are summarized here of daily antibiotics can successfully later, and are often related to obvious (Infectious Disease specialists Marlene lower postoperative infection rates. tissue melt and leak. Autoimmune Durand, MD and Irmgard Behlau, MD In the past, postoperative bacterial diseases (Stevens-Johnson syndrome, have been consulted): endophthalmitis frequently occurred ocular pemphigoid, graft vs. host after any type of keratoprosthesis, disease, atopy, etc.) have been the most 1. For the standard patient receiving a which contributed to the poor vulnerable to infection. The events have, Boston Keratoprosthesis Type I after reputation of the procedure. Gram- in the most cases, resulted in rapid multiple graft failures, we usually give positive bacteria, by far, have been destruction of the eye. a fourth-generation fluoroquinolone continues on page 3

A Boston Keratoprosthesis update from the Harvard Medical School/ Mass. Eye and Ear Department of BOSTON Titanium back plates await FDA approval KPro itanium is a material that has widespread application in medical bioengineering. For example, it is used in joint replacement, tooth implants, Tpacemakers, brain shunts, and artificial limbs; moreover, it has the reputation of being very inert and tissue friendly. Because of its versatility and strength, the news Boston KPro team tested titanium as a potential material for making the back plate of the Boston KPro. As a first step, tissue culture experiments with epithelial cells showed titanium to be better tolerated than polymethyl methacrylate (PMMA).1 Subsequent studies in rabbits and, since 2005, in patients have demonstrated that In this issue: titanium is clearly superior in several respects: it can be machined to a very thin, yet strong and unbreakable plate; appears to cause less postoperative inflammation in Antimicrobial prophylaxis for life: the anterior chamber than PMMA; and demonstrates statistically lower rates of the as important as ever...... 1 frequency and severity of retroprosthetic membranes.2,3 Another advantage is that titanium is non-magnetic and, thus, compatible with MRI testing. Titanium back plates await FDA approval...... 2 CE Mark will make KPro available in Europe...... 3 Profiles of distinguished KPro surgeons...... 4 The Boston KPro Team...... 6 Full-Time KPro Clinical & Research Fellows...... 7 Boston KPro Literature...... 8 Poster Presentations ...... 10 American Academy of Ophthalmology Meeting...... 11 KPro Events 2011-12...... 11 Titanium back plates of various dimensions and designs. Upper row: 7.0 mm, 8.5 mm and 9.5 mm diameter.

Since the titanium back plate is a new material, FDA approval is required before we can market and distribute this type of KPro in the United States. Several stringent FDA measures must be met before approval is granted. For example, the FDA has deemed the ethylene oxide sterilizers in local Boston area hospitals insufficient for “industrial” use; this requires that we send all packaged KPros to a South Carolina facility where long-term feasibility testing is underway. We anticipate that these measures, coupled with the FDA processing cycle, will result in a six to 12 month timeframe before we receive FDA marketing approval. Clearly, our KPro manufacturing has entered a new, more complex phase. The Boston KPro 1. Ament JD, Spurr-Michaud S, Dohlman CH, Gipson IK. The Boston Keratoprosthesis: comparing corneal newsletter is published cell compatibility with titanium and PMMA back plates. Cornea 2009; 28:808-811. 2. Dohlman CH, Todani A, Ament JD, Chodosh J, Ciolino JB, Colby KA, Pineda R, Belin MW, Aquavella JV, once annually. Graney J. Titanium vs. PMMA back plates for Boston Keratoprosthesis: Incidence of retroprosthetic mem- brane. Invest Ophthalmol Vis Sci, 2009; ARVO poster # 1505. Co-Editors: 3. Todani A, Ciolino JB, Ament JD, Colby KA, Pineda R, Belin MW, Aquavella JV, Chodosh J, Dohlman CH. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol 2011; Rhonda Walcott-Harris in press. James Chodosh, MD, MPH

Claes Dohlman, MD, PhD 2 | BOSTON KPro news | FALL 2011 CE Mark will make KPro available in Europe n order to distribute the Boston keratoprosthesis throughout Boston KPro Usage Europe, which includes 27 countries with a population of 1,200 Iapproximately 500 million, we recently began the process to obtain CE Marking. CE Marking is a mandatory conformity 1,000 mark for medical products marketed in the European Union (EU), along with Iceland, Liechtenstein, and Norway. The 800 term, CE stands for “European Conformity” and is considered a quality mark similar to FDA device approval in the U.S. CE 600 Marking indicates compliance with EU legislation regarding health, safety and environmental concerns related to the design 400 and manufacturing of a medical device. CE Marking indicates to any government official that the product can be marketed, 200 and ensures the free movement of the product within the EU.

Fully meeting the rigorous EU standards necessitates changing 0 where and how we sterilize our devices, and upgrading many of 2002 2003 2004 2005 2006 2007 2008 2009 2010 International Other U.S. MEEI our internal procedures. Once all of these changes are in place, we expect to receive approval within a year from now. Since 2002, about 6,000 KPro devices have been implanted worldwide. continued from page 1 starting at 2-4 times daily and tapered over 1-2 months, We do not routinely give antifungal prophylaxis in Boston. followed by once-daily polymyxin B/trimethoprim (generic In hot, humid areas, brief periodic bursts of antifungals may form of Polytrim™) for life. The latter drug is broad spectrum be necessary (e.g. Amphotericin B 0.15% twice daily for 1 with sufficient gram-positive coverage; it is also inexpensive. or 2 weeks every 3 months). If fungal colonization of the 2. In autoimmune patients, chemical burns, and only soft contact lens is identified, lens exchange plus a period of eyes, we initially give vancomycin (14 mg/ml with 0.005% Amphotericin is advisable. In fungal keratitis (white sheen benzalkonium) once daily plus a fluoroquinolone initially around the KPro stem) or outright endophthalmitis, the 2-4 times daily, tapered to once or twice daily (for both) for addition of systemic antifungals is necessary. Prognosis is life. Inclusion of vancomycin is important even though it has usually good as long as the infection is identified early. to be specially made up. Eventually, fluoroqinolone can be With the above listed prophylactic medication, the rate substituted by the much cheaper polymyxin B/trimethoprim of infections can be kept very low. Our present rate of as the second agent, for life. destructive endophthalmitis within five years postoperatively Under any circumstances, compliance with daily medication is 2% (mostly due to non-compliance). This includes a high for life is extremely important and must be emphasized percentage of autoimmune cases. However, lack of compliance repeatedly. with daily medication, which is especially challenging in developing countries for many reasons (e.g. cost of medical Corticosteroids are usually given topically as prednisolone supplies or scarcity of medical personnel) is still very acetate 1.0% with the same regimens as following penetrating troubling. A significant research effort is currently underway keratoplasty. Treatment is often started with 4 times daily, to make the Boston KPro simpler, less expensive and — most gradually tapered to once daily over 2-3 months and, in of all — safer in the long run. We hope to have some good many cases, eventually stopped. Caution is urged regarding news in this respect in the near future. long-term steroids in autoimmune diseases where they can contribute to tissue melt.

Visit us! www.meei.harvard.edu/shared/ophtho/cornea2.php

BOSTON KPro news | 3 Profiles of distinguished KPro surgeons

Dr. Virender Singh Sangwan the National Technology Prize by the completed his basic medical education Department of Biotechnology in 2007. and ophthalmology training at Dr. Sangwan has served as Field Maharshi Dayanand University, Medical Director of Orbis International, Rohtak, Haryana, and a cornea Inc., NY and has lectured extensively. fellowship at LV Prasad Eye Institute He is the recipient of numerous (LVPEI) in Hyderabad. He went on to awards and serves on several editorial complete an immunology and uveitis boards. Dr. Sangwan is presently fellowship at Harvard Medical School in the Coordinator for Collaborative 1998. He is currently Associate Director Research Projects between LVPEI and and Head of the Cornea and Anterior VisionCRC, a cooperative research Segment, Ocular Immunology & center initiative of the Australian Uveitis Services at LVPEI. government. He is also an Adjunct Dr. Sangwan is noted for his Associate Professor at the University spirit of innovation and ability to School of Medicine & Dentistry, Virender Singh Sangwan, MD translate basic science discoveries University of Rochester, New York, into clinical applications. Among USA. Dr. Sangwan also has been deeply his accomplishments, Dr. Sangwan involved in the eye banking movement perfected the method of limbal stem in India. cell culturing to produce transparent, Dr. Sangwan is married to Vandana, a stitchable epithelium, and successfully dentist, and they have two children — transplant them to patients. His daughter, Twinkle and son, Sahil. work represents the largest successful human trial of stem cell technology Dr. Jimmy K. Lee is the Director of in the world, and has enabled him Cornea and Refractive Surgery at the to restore vision to over 600 patients Yale Eye Center. He specializes in laser blinded by burns and damage to the vision correction surgery, including ocular outer surface; his work has LASIK, LASEK, PRK and PTK. His been published in the journal Nature. surgical expertise also includes complex Additionally, he devised a method to cataract surgery and artificial cornea co-culture conjunctival and limbal surgery. Dr. Lee is an experienced stem cells and to use the resulting Boston KPro surgeon. tissue to restore vision in extreme Jimmy K. Lee, MD Dr. Lee’s research interests include cases of ocular surface damage. For new technologies in refractive these contributions, Dr. Sangwan was surgery and improving surgical awarded the Shanti Swarup Bhatnagar techniques for DSEK (Descemet’s Prize in Medical Sciences in 2006, and

4 | FALL 2011 | NUMBER 8 Profiles of distinguished KPro surgeons

Stripping Endothelial Keratoplasty). the factors that contribute to corneal A member of the American Academy melts (epithelial invasion vs. stromal of Ophthalmology and American necrosis), and contributed to the Society of Cataract and Refractive article “Keratoprosthesis: preoperative Surgery, he has published many peer- prognostic categories,” published in the reviewed articles and is a scientific journal Cornea in 2001, an article which reviewer for numerous ophthalmology remains current today. During the latter journals. In addition, he frequently part of his fellowship, he assisted with lectures on refractive surgery and implementing the KPro program in the at national and Dominican Republic. international scientific meetings. After completing his fellowship, Dr. Lee graduated Phi Beta Kappa from Dr. Abad returned to his native Johns Hopkins University and obtained Colombia in 1997, where he pioneered his medical degree from Cornell the introduction of the Boston KPro. University Medical College. Following Since then, he has performed surgery his residency at Albert Einstein on 47 patients (43 with the new model Juan Carlos Abad, MD Montefiore Hospital, he completed a since 2004), helping to restore sight fellowship in Cornea, External Diseases, to long-standing blind patients. In and Refractive Surgery at the Wilmer 2010, Dr. Abad presented at the World Eye Institute of The Johns Hopkins Cornea Conference V1 (Boston) on Hospital. He is a Diplomate of the improving KPro retention through American Board of Ophthalmology. the use of medroxyprogestrone, doxycycline, and by avoiding MMP Dr. Juan Carlos Abad received activating antibiotics and his medical degree from the agents. He frequently lectures and gives Institute of Health Sciences CES in courses on the topic throughout Latin Medellin, Columbia and completed America. He is currently advocating his ophthalmology residency at an aphakic approach with a complete Georgetown University Medical pars plana vitrectomy (in most cases) Center, DC. As a cornea fellow at to decrease inflammation, interdevice Mass. Eye and Ear (’95-’97), Dr. Abad membranes, facilitate glaucoma shunt worked on the KPro to develop an insertion and long-term success (no animal model that could be tested for vitreous blockage), and to facilitate different device retention strategies; KPro re-dos when needed. Dr. Abad he also studied the histology of runs a private practice in Medellin, explanted KPros to better understand Colombia.

BOSTON KPro news | 5 Claes Dohlman, MD, PhD James Chodosh, MD, MPH Kathryn Colby, MD, PhD Translational Research Surgery, Translational Research Surgery, Clinical Research Mass. Eye and Ear Mass. Eye and Ear Mass. Eye and Ear TEAM ro

Roberto Pineda II, MD Samir Melki, MD, PhD Daniel Kohane, MD, PhD Surgery, Clinical Research Surgery, IOP Transducers Bioengineering Mass. Eye and Ear Mass. Eye and Ear MIT/Children’s Hospital Boston

Ilene Gipson, PhD Eli Peli, MSc, OD Lucy Shen, MD Enzymology Glaucoma Schepens Eye Research Institute Schepens Eye Research Institute Mass. Eye and Ear

Jill Beyer, OD Lucy Young, MD, PhD Contact Lens Retina Mass. Eye and Ear Mass. Eye and Ear THE BOSTON KP BOSTON THE 6 | BOSTON KPro news | FALL 2011 Kyung Jae Jeong, PhD Michinao Hashimoto, PhD Biointegration Glaucoma Shunt MIT MIT/Children’s Hospital Boston

Irmgard Behlau, MD Fabiano Cade, MD Borja Salvador, MD Antimicrobial Coating and Chemical Burns Surgical Innovations Infection Prevention Mass. Eye and Ear Mass. Eye and Ear Mass. Eye and Ear CLINICAL & RESEARCH FELLOWS Samer Arafat, MD Rony Sayegh, MD Eleftherios Paschalis, PhD Metalloproteinase Inhibitors Optics Bioengineering Mass. Eye and Ear Mass. Eye and Ear Mass. Eye and Ear ro

Andrea Cruzat, MD Anita Nathan Shukla, MD Surgical Innovations Surgical Innovations Mass. Eye and Ear Mass. Eye and Ear

FULL-TIME KP FULL-TIME BOSTON KPro news | 7 Boston KPro Literature (2010 to present)

Sayegh RR, Avena Diaz L, Vargas- African Experience. Arch Ophthalmol Khalifa YM, Davis D, Mamalis N, Martin F, Webb RH, Dohlman CH, 2010:128:795-797. Moshirfar. Epithelial growth over Peli E. Optical functional properties the optic surface of the type I Boston Tsui I, Uslan DZ, Hubschman JP, of the Boston Keratoprosthesis. Invest Keratoprosthesis: histopathology and Deng SX. Nocardia farcinica Infection of Ophthalmol Vis Sci 2010; 51:857-863. implications for biointegration. Clin a Baerveldt implant and endophthalmitis Ophthalmol 2010; 4:1069-1071. Dohlman CH, Grosskreutz CL, Chen TC, in a patient with a Boston Type I Pasquale LR, Rubin PAD, Kim EC, Keratoprosthesis. Glaucoma 2010; Nallasamy S, Colby K. Keratoprosthesis: Durand M. Shunt to divert aqueous 19:339-340. Procedure of Choice for Corneal humor to distant epithelialized cavities Opacities in Children? Semin Vajaranant TS, Blair MP, McMahon T, after Keratoprosthesis surgery. Risk of Ophthalmol 2010; 25(5-6):244-248. Wilensky JT, de la Cruz J. Special infection. Glaucoma 2010; 19:111-115. considerations for pars plana tube- Stacy RC, Jakobiec FA, Michaud NA, Dunlap K, Chak G, Aquavella JV, shunt placement in Boston Type I Dohlman CH, Colby KA. Charac­ Myrowitz E. Utine CA, Akpek E. Keratoprosthesis. Arch Ophthalmol 2010; terization of retro-keratoprosthetic Short-term visual outcomes of Boston 128:1480-1482. membranes in the Boston Type I Type I Keratoprosthesis implantation. keratoprosthesis. Arch Ophthalmol 2011; Garrick C, Aquavella JV. A safe Nd:YAG Ophthalmology 2010; 117:687-692. 129:310-316. retroprosthetic membrane removal Garcia JP, Jr., Ritterband DC, Buxton DF, technique for keratoprosthesis. Cornea Ament JD, Stryjewski TP, Pujari S, de la Cruz J. Evaluation of the stability of 2010;29:1169-1172. Siddique S, Papaliodis GN, Chodosh J, Boston Type I Keratoprosthesis-Donor Dohlman CH. Cost effectiveness of the Utine CA, Gehlbach PL, Zimer-Galler I, cornea interface using anterior segment Type II Boston Keratoprosthesis. Eye Akpek EK. Permanent keratoprosthesis optical coherence tomography. Cornea 2011; 25:342-349. combined with pars plana vitrectomy 2010; 29:1031-1035. and silicone oil injection for visual Chodosh J, Dohlman CH. Indications for Tay E, Utine CA, Akpek EK. Crescenteric rehabilitation of chronic hypotony and keratoprosthesis. In: Krachmer J, Mannis amniotic membrane grafting in . Cornea 2010; 29:1401- M, Holland E, eds. Cornea 3rd ed., Keratoprosthesis-associated cornea melt. 1405. St. Louis; Mosby-Year Book, Inc, 2011 Arch Ophthalmol 2010; 128:779-782. Vol. II:1689-1691. Ciralsky J, Papaliodis GN, Dohlman CH, Yildiz E, Saad C, Eagle R, Ayers B, Chodosh J. Keratoprosthesis in Oliveira L, Cade F, Dohlman CH. Cohen E. The Boston Keratoprosthesis autoimmune disease. Ocular Keratoprosthesis in the fight against in 2 patients with autoimmune Immunology and Inflammation 2010; corneal blindness in developing polyendocrinopathy. Cornea 2010; 18:275-280. countries. (Editorial) Arq Bras Oftalmol 29:354-356. 2011; 74:5-6. Pineles SL, Ela-Dalman N, Harissi-Dagher M, Khan BF, Rosenbaum AL, Aldave AJ, Velez FG. Dohlman CH, Cade F, Pfister RR. Dohlman CH. The Boston Binocular visual function in patients Chemical burns to the eye: Paradigm Keratoprosthesis. In: Corneal with Boston Type I Keratoprosthesis. shifts in treatment (Editorial) Cornea Transplantation. Rasik B Vajpayee, ed, Cornea 2010;29:1397-1400. 2011; 30:613-614. Namrata Sharma, Geoffrey C Tabin and Klufas MA, Colby KA. The Boston Dohlman CH, Gelfand L, Walcott- Hugh R Taylor, co-eds. Vajpayee Brothers keratoprosthesis. Int Ophthalmol Clin Harris R, Moar ML. The Boston Medical Publishers. New Delhi, 2010. 2010;50: 161-175. Keratoprosthesis — Users Manual. Ament JD, Stryjewski TP, Ciolino JB, Massachusetts Eye and Ear Georgalas I, Kanelopoulos AJ, Petrou P, Todani A, Chodosh J, Dohlman CH. Infirmary, 2011. Ladas I, Gotzaridis E. Presumed Cost-effectiveness of the Boston endophthalmitis following Boston Greiner MA, Li JY, Mannis MJ. Keratoprosthesis. Am J Ophthalmol Keratoprosthesis treated with 25 gauge Longer-Term Vision Outcomes and 2010; 149: 221-228. vitrectomy: a report of three cases. Complications with the Boston Type Ament JD, Todani A, Pineda II R, Shen Graefes Arch Clin Exp Ophthalmol 2010; I Keratoprosthesis at the University of TT, Aldave AJ, Dohlman CH, Chodosh J. 248:447-450. California, Davis. Ophthalmology 2011; Global corneal blindness and the Boston 118:1543-1550. Basu S. Two unusual indications of Keratoprosthesis Type I (Editorial). Am J the Boston Keratoprosthesis: Limbal Basu S, Taneja M, Sangwan VS. Boston Ophthalmol 2010; 149: 537-539. stem cell deficiency in end stage vernal Type I Keratoprosthesis for severe Ament JD, Tilahun Y, Mudawi E, keratoconjunctivitis and Mooren’s blinding vernal keratoconjunctivitis and Pineda R. Role for ipsilateral ulcer. Webmedcentral: Article Mooren’s ulcer. Int Ophthalmol 2011; autologous corneas as a carrier for ID:WMC00813.2010:1-5. 31:219-222. the Boston Keratoprosthesis: The

8 | FALL 2011 | NUMBER 8 Banitt M. Evaluation and management Todani A, Ciolino JB, Ament JD, Colby Jeong KJ, Wang L, Stefanescu CF, of glaucoma after keratoprosthesis. KA, Pineda R, Belin MW, Aquavella Lawlor M, Polat J, Dohlman CH, Review. Curr Opin Ophthalmol 2011; JV, Graney JM, Chodosh J, Dohlman Langer RS, Kohane DS. Polydopamine 22:133-136. CH. Titanium back plate for a PMMA coatings for biointegration. Soft Matter, keratoprosthesis: Clinical outcomes. in press. Colby KA, Koo EB. Expanding Graefes Arch Clin Exp Ophthalmol, indications for the Boston Beyer J, Todani A, Dohlman CH. in press. Keratoprosthesis. Curr Opin Ophthalmol Visually debilitating deposits on soft 2011; 22:267-273. Pujari S, Siddique S, Dohlman CH, contact lenses in keratoprosthesis Chodosh J. Boston Keratoprosthesis patients. Cornea, in press. Li JY, Greiner MA, Brandt JD, Lim MC, Type II: The Massachusetts Eye and Ear Mannis MJ. Long-term complications Kumar R, Dohlman CH, Infirmary experience. Cornea, in press. associated with glaucoma drainage Chodosh J. Oral acetazolamide after devices and Boston Keratoprosthesis. Wang L, Chodosh J, Huang Y, Dohlman keratoprosthesis in Stevens-Johnson Am J Ophthalmol 2011; 152:209-218. CH. Boston Keratoprosthesis in China Syndrome. Submitted to J Glaucoma. (in Chinese) J Chin Ophthalmol, in press. Robert MC, Harissi-Dagher M. Boston Jardeleza MSR, Rheaume MA, Type 1 keratoprosthesis: the CHUM Jun JJ, Siracuse-Lee DE, Daly MK, Chodosh J, Dohlman CH. Young L. experience. Can J Ophthalmol 2011; Dohlman CH. Keratoprosthesis. Retinal detachment after Boston 46:164-168. In: Cornea and External Eye Diseases, Keratoprosthesis: incidence, 2nd ed. Krigelstein GK, Weinreb RN, predisposing factors and visual Nascimento HM, Oliveira LA, Höfling- eds. Springer Verlag, Berlin, in press. outcomes. Submitted to Ophthalmology. Lima AL. Infectious keratitis in patients undergoing Boston Type 1 Haddadin R, Dohlman CH. Behlau I, Mukjerjee K, Todani A, keratoprosthesis (Boston KPro) Keratoprosthesis in congenital Tisdale AS, Wang L, Cade F, Leonard E, procedure: case series. Arq Bras Oftalmol hereditary endothelial dystrophy. Digital Zakka F, Gilmore MS, Jakobiec FA, 2011; 74:127-129. Journal Ophthalmology, in press. Zakka FR, Dohlman CH, Klibanov AM. Biocompatibility and biofilm inhibition Moshirfar M, Neuffer MC, Kinard K, Chan CC, Holland EJ. Endophthalmitis of N,N-hexyl, methyl-polyethylenimine Lependu MT, Sikder S. Femtosecond- after Boston Type I Keratoprosthesis bonded to Boston Keratoprosthesis assisted preparation of donor tissue for implantation. Cornea, in press. artificial cornea. Biomaterials, in press. Boston Type 1 Keratoprosthesis. Clin Chan CC, Holland EJ, Sawyer WI, Ophthalmol 2011; 5:1017-1020. Rudnisky CJ, Belin MW, Todani A, Neff KD, Peterson MR, Riemann CD. Zerbe BJ, Ciolino JB. Risk factors for Utine CA, Tzu J, Dunlap K, Akpek EK. Boston Type 1 keratoprosthesis with the development of retroprosthetic Visual and clinical outcomes of silicone oil for treatment of hypotony in membranes with Boston explantation versus preservation of the prephthisical eyes. Cornea, in press. Keratoprosthesis type 1: multicenter intraocular lens during keratoprosthesis Keating A, Pineda R II. Trichosporon study results. Ophthalmology, in press. implantation. J Cataract Refract Surg asahii keratitis in a patient with a Type 1 2011; 37:1615‑1622.34 Soledad Cortina M, Porter IW, Boston Keratoprosthesis and contact Sugar J, de la Cruz J. Boston Type I Iyer G, Srinivasan B, Gupta J, lens. Eye Contact Lens, in press. keratoprosthesis for visual rehabilitation Rishi P, Sen PR, Bhende P, Sejpal K, Yu F, Aldave AJ. The Boston in a patient with gelatinous drop-like Gopal L, Padmanabhan P. Boston Keratoprosthesis in the management corneal dystrophy. Submitted to Cornea. Keratoprosthesis for keratopathy in of corneal limbal stem cell deficiency. eyes with retained silicone oil — A new Iyer G, Gupta N, Srinivasan B, Cornea, in press. indication. Cornea, in press. Padmanabhan. Boston Type I Wang L, Jeong KJ, Chiang HH, Keratoprosthesis — The Indian Kammerdiener LL, Aquavella JV, Zurakowski D, Behlau I, Chodosh J, experience. Submitted to Cornea. Harissi-Dagher M, Lynch ML, Dohlman CH, Langer RS, Kohane DS. Dohlman CH, Chodosh J, Ciolino J. Hydroxyapatite for keratoprosthesis Soft contact lens retention after Boston biointegration. Invest Ophthalmol Vis We apologize for Keratoprosthesis: The importance Sci, in press. of preoperative diagnosis. Am J inadvertent omissions. Ophthalmol, in press. Todani A, Behlau I, Fava M, CadeF, Cherfan D, Zakka FR, Jakobiec FA, Gao Cade F, Grossskreutz CL, Tauber A, Y, Dohlman CH, Melki S. Intraocular Dohlman CH. The role of glaucoma pressure measurement by radiowave after Boston Keratoprosthesis in severe telemetry. Invest Ophthalmol Clin Sci, chemical burns. Cornea, in press. in press.

BOSTON KPro news | 9 Poster Presentations

American Academy of Ophthalmology Ashley Dahl, Kristen M. Hawthorne, Fernanda P. Magalhaes, Heloisa M. (2010) Bradford Mitchell, Gerald McGwin, Nascimento, Ana L. Hofling- John S. Parker. Early sight restoration Lima, Lauro A. Oliveira. Post- Deepak Sobti, Brendan M. McCleary, and high retention after Boston operative regimen of Boston Type I William G. Gensheimer, Garrick Keratoprosthesis in non-autoimmune Keratoprosthesis with topical 0.5% Chak, Matthew D. Gearinger, Mina patients. Poster # D854 moxifloxacin and 5% povidone-iodine. Chung, James Aquavella. Pediatric Poster # D863 keratoprosthesis: Outcomes and quality Sahar Kohanim, Tulay Cakiner-Egilmez, of life. Poster # 58. Robert W. Dunphy, Mary K. Daly. Alex W. Cohen, Michael D. Wagoner, RTVue CAM anterior segment OCT Anna Kitzman, Kenneth M. Goins. Javaneh Abbasian. Ultrasound imaging of epithelial lip overriding front Outcomes of corneal transplantation biomicroscopy used preoperatively for plate of Boston Type I Keratoprosthesis. with the Boston Type I Keratoprosthesis. surgical planning in patients undergoing Poster # D855 Poster # D864 Boston KPro Type 1. Poster # 353. Travis C. Rumery, Shahzad I. Mian, Julia C. Talajic, Sebastien Gagne, Younes Amar P. Patel, Joseph T. Nezgoda, Syril Fernando Heitor de Paula. Outcomes of Agoumi, Mona Harissi-Dagher. Long- Dorairaj, Tiago S. Prata, John A. Seedor, endocyclophotocoagulation in Boston term results regarding the impact of David C. Ritterband. Surgical outcomes Type 1 Keratoprosthesis. Poster # D856 glaucoma on vision following Boston of the Boston Keratoprosthesis. Poster Keratoprosthesis Type I surgery. Poster # 359. Joann J. Kang, Maria S. Cortina, Jose # 1635 De la Cruz. Visual outcomes of Boston The Association for Research in Vision Keratoprosthesis implantation as the Yvonne I. Chu, Christopher C. Shen, and Ophthalmology (2011) primary penetrating corneal procedure. Michael D. Straiko, Crawford Downs, Poster # D857 Neda Shamie, Stuart K. Gardiner, Joshua H. Hou, Jose De la Cruz, Ali R. Steven L. Mansberger. Assessment Mark Krakauer, Shivani Gupta, Asim Djalilian. Predictors of keratoplasty of intraocular pressure in eyes with V. Farooq, Jose De la Cruz, Maria S. failure after keratolimbal allograft keratoprosthesis. Poster # A612 transplantation and long-term outcomes Cortina, Peter Setabutr. Oculoplastic of Boston Keratoprosthesis implantation considerations in keratoprosthesis Jennifer S. Huang, Simon K. Law, as subsequent salvage therapy in ocular surgery. Poster # D858 Fei Yu, Joann A. Giaconi, Anne L. Coleman, Joseph Caprioli, Anthony surface disease. Poster # D847 Joseph Panarelli, Anne Ko, Julian P. Aldave. Glaucoma management in Garcia, Paul A. Sidoti, Michael R. Banitt. Pejman Bakhtiari, Jeffry Welder, Clara patients undergoing Boston Type I Angle closure by anterior segment Chan, Jose De la Cruz, Edward J. Keratoprosthesis implantation. Poster optical coherence tomography after Holland, Ali R. Djalilian. Surgical and # A68 visual outcomes of the Type 1 Boston Boston Keratoprosthesis. Poster # D859 Basu S, Senthil S, Sangwan VS. Keratoprosthesis for the management of Lee Kiang, Mark I. Rosenblatt, Rachel Correlation of anterior chamber angle aniridic fibrosis syndrome in congenital Sartaj, Donald J. D’Amico, Kimberly C. morphology with progression of aniridia. Poster # D848 Sippel. Surface Epithelialization of the glaucoma in eyes with Boston Type I Type I Boston Keratoprosthesis Front Danli L. Xing, Christine Chiou, Mark Keratoprosthesis. Poster # 85 Mannis, John Keltner. Glaucoma Plate. Poster # D860 Mines MJ, Ryan DS, Sia RK, detection in Boston Keratoprosthesis Jose De la Cruz, Maria S. Cortina, Weber E, Pasternak J, Stutzman RD, patients. Poster # D852 Jin-Hong Chang, Dimitri T. Azar. Wroblewski KJ, Bower KS. On the case: Scanning electron microscopy analysis Ofelya Gevorgyan, Anna Hovakimyan, Deconstructing a keratoprosthesis. of explanted keratoprostheses. Poster Anthony J. Aldave. Complications Poster # 67 and outcomes of Boston Type 1 # D861 Keratoprosthesis surgery in Armenia. Trucian A. Ostheimer, Jose de la Cruz, Poster # D853 Maria S. Cortina. Corneal graft thinning in Boston Type 1 Keratoprosthesis patients. Poster # D862

10 | FALL 2011 | NUMBER 8 You’re invited. Please join us!

American Academy of Ophthalmology Meeting KPro Events 2011-12 October 22-25, 2011 | Orlando, Fl Schedule of Events 2nd EuCornea Congress September 16-17, 2011 Friday, October 21 Reed Messe Wien GmbH, n 8:30 a.m. – 4:30 p.m. Messeplatz 1, PF 277, A-1021 Cornea Society/EBAA Fall Educational Conference Vienna, Austria Rosen Centre Hotel 27th Biennial Cornea Conference Sunday, October 23 September 30-October 1, 2011 n 11:37 – 11:57 a.m. Starr Center for Scientific Whitney G. Sampson Lecture: “Artificial Corneas and Contact Lenses” Communications Claes H. Dohlman, MD, PhD 185 Cambridge Street, Boston, MA Orange County Convention Center, Room W311 n 10:15 a.m. – 12:30 p.m. European Association for Vision Instruction Course: “Corneal Surgical Tips for 2011” and Eye Research 2011 Congress Senior Instructor: David G. Huang, MD October 5-8, 2011 Orange County Convention Center, Room W203c Creta Maris Convention Center n 3:15 – 5:30 p.m. I nstruction Course: “Surgery for Severe Corneal and Ocular Surface Disease” Crete, Greece Senior Instructor: Gunther Grabner, MD Orange County Convention Center, Room W104a World Ophthalmology Congress 2012 Monday, October 24 February 16-20, 2012 n 7:00 – 8:30 a.m. Abu Dhabi National Exhibitions B oston KPro Users Breakfast: James Chodosh, MD, MPH, moderator Centre Hilton Orlando, Lake Lucerne Room Abu Dhabi, United Arab Emirates For further information contact [email protected] n 7:00 – 8:30 a.m. Cornea Day Pediatric Keratoplasty Association, Breakfast at AAO Friday, April 20, 2012  Kathryn Colby, MD, PhD: “Pediatric Keratoprosthesis: Promise and Perils,” McCormick Place West The eabodyP Orlando, Room Bayhill 18 Chicago, Illinois n 9:00 – 11:15 a.m. Boston KPro Course: “The Boston Keratoprosthesis: Essentials for the The American Society of Cataract Beginning and Experienced Surgeon” Senior Instructor: Anthony J. Aldave, MD and Refractive Surgery Orange County Convention Center, Room W309a April 20-24, 2012 Chicago, Illinois Tuesday, October 25 Applications for KPro course n 7:30 – 8:30 a.m. submitted, Senior Instructor: Breakfast with the Experts: Moderator: Peter Zloty, MD José de la Cruz Orange County Convention Center, Room Hall A1 n 2:00 – 4:15 p.m. Instruction Course: “Extreme Cornea: Diagnostic and Management Dilemmas in Your Practice” Senior Instructor: Ula Jurkunas, MD Orange County Convention Center, Room W204c n 10:15 a.m. – 12:30 p.m. Instruction Course: “Interdisciplinary Approach to Keratoprosthesis Surgery and Management from the Subspecialist’s Perspective” Senior Instructor: Jose de la Cruz, MD Orange County Convention Center, Room W207c

BOSTON KPro news | 11 243 C harles Street, Boston, MA 02114

E-mail your contact information to: [email protected] BOSTON or send via fax to: 617-573-4369 or 617-573-4324 KPro e-news NAME

STREET ADDRESS

Please let us know CITY, STATE, ZIP CODE if you would like to receive the e-mail E-MAIL ADDRESS version of Boston KPro News or if your mailing PHONE NUMBER address has changed.

FAX NUMBER